糖皮质激素在 COVID-19 管理中的作用。
The Role of Glucocorticoids in the Management of COVID-19.
机构信息
Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Clinic Carl Gustav Carus, TU Dresden, Dresden, Germany.
Center for Regenerative Therapies Dresden, TU Dresden, Dresden, Germany.
出版信息
Horm Metab Res. 2021 Jan;53(1):9-15. doi: 10.1055/a-1300-2550. Epub 2020 Nov 18.
Coronavirus disease 2019 (COVID-19), caused by an infection with the novel coronavirus SARS-CoV-2, has resulted in a global pandemic and poses an emergency to public health systems worldwide. COVID-19 is highly infectious and is characterized by an acute respiratory illness that varies from mild flu-like symptoms to the life-threatening acute respiratory distress syndrome (ARDS). As such, there is an urgent need for the development of new therapeutic strategies, which combat the high mortality in severely ill COVID-19 patients. Glucocorticoids are a frontline treatment for a diverse range of inflammatory diseases. Due to their immunosuppressive functions, the use of glucocorticoids in the treatment of COVID-19 patients was initially regarded with caution. However, recent studies concluded that the initiation of systemic glucocorticoids in patients suffering from severe and critical COVID-19 is associated with lower mortality. Herein we review the anti-inflammatory effects of glucocorticoids and discuss emerging issues in their clinical use in the context of COVID-19.
新型冠状病毒病 2019（COVID-19）是由新型冠状病毒 SARS-CoV-2 感染引起的，已在全球范围内引发大流行，对全球公共卫生系统构成紧急威胁。COVID-19 具有高度传染性，其特征是急性呼吸道疾病，从轻度流感样症状到危及生命的急性呼吸窘迫综合征（ARDS）不等。因此，迫切需要开发新的治疗策略，以应对重症 COVID-19 患者的高死亡率。糖皮质激素是治疗多种炎症性疾病的一线药物。由于其免疫抑制作用，糖皮质激素在 COVID-19 患者治疗中的应用最初受到谨慎对待。然而，最近的研究得出结论，在患有严重和危急 COVID-19 的患者中开始使用全身糖皮质激素与较低的死亡率相关。本文综述了糖皮质激素的抗炎作用，并讨论了 COVID-19 背景下其临床应用中出现的新问题。
Zotero 插件